Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART19.1 in refractory SLE
NCT06189157Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Aug 2024
- Primary completion
- Sep 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of zorpocabtagene autoleucel in systemic lupus erythematosus (SLE), sponsored by Miltenyi Biomedicine GmbH. Started Aug 2024; status: recruiting.
02
Drugs
zorpocabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06189157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189157.